**BACKGROUND**

- AKT信号 pathway is aberrantly dysregulated in a wide range of tumor types.
- Extensive molecular evidence validates the pathway as a target in cancer.

**RESULTS**

As of 31 Aug 2015, 107 subjects have been enrolled and treated including 62 in the dose escalation cohorts and 25 in the expansion cohort.

### Table 5. Tumor Response in Expansion Cohort (%)

<table>
<thead>
<tr>
<th>PR</th>
<th>NE</th>
<th>PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>10%</td>
<td>25%</td>
</tr>
</tbody>
</table>

**CONCLUSIONS**

- ARO 092 has a manageable safety profile at the RP2Ds and schedules.
- The drug-related adverse events reported are hyperglycemia, skin rash, diarrhea, vomiting, mucositis and transaminase increase. Most of the adverse events are mild to moderate. The most common drug-related severe (Grade 3/4) adverse events include hyperglycemia and skin rash.
- Maximal plasma levels (Cmax) ranged from a mean of 1867 nm for the 200 mg QD, GW2 to a mean of 1403 nm for the 200 mg BID QW expansion cohorts.
- ARO 092 has demonstrated preliminary anti-cancer activities in the expansion cohort:
  - Partial responses have been observed in the expansion cohort in 4 subjects including 2 subjects with AKT1 E17K mutation (follicular lymphoma and breast), 1 subject with PIK3CA mutations, and 1 subject with AKT1 and PIK3CA mutations.
  - Long-term disease stabilization and tumor shrinkage has been noted in subjects with lymphoma and other tumors.
- Patient accrual continues in subjects with AKT1 and PIK3CA mutations.

---

**OBJECTIVES**

- Safety and tolerability in subjects with cancers.
- Pharmacokinetic and pharmacodynamic activity; MTD and RP2D; preliminary evidence of activity.

**STUDY DESIGN AND METHODS**

- Extensive molecular evidence validates the pathway as a target in cancer.
- AKT signal pathway is aberrantly dysregulated in a wide range of tumor types.

---

**RESULTS**

As of 31 Aug 2015, 107 subjects have been enrolled and treated including 62 in the dose escalation cohorts and 25 in the expansion cohort.

### Table 5. Tumor Response in Expansion Cohort (%)

<table>
<thead>
<tr>
<th>PR</th>
<th>NE</th>
<th>PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>10%</td>
<td>25%</td>
</tr>
</tbody>
</table>

**CONCLUSIONS**

- ARO 092 has a manageable safety profile at the RP2Ds and schedules.
- The drug-related adverse events reported are hyperglycemia, skin rash, diarrhea, vomiting, mucositis and transaminase increase. Most of the adverse events are mild to moderate. The most common drug-related severe (Grade 3/4) adverse events include hyperglycemia and skin rash.
- Maximal plasma levels (Cmax) ranged from a mean of 1867 nm for the 200 mg QD, GW2 to a mean of 1403 nm for the 200 mg BID QW expansion cohorts.
- ARO 092 has demonstrated preliminary anti-cancer activities in the expansion cohort:
  - Partial responses have been observed in the expansion cohort in 4 subjects including 2 subjects with AKT1 E17K mutation (follicular lymphoma and breast), 1 subject with PIK3CA mutations, and 1 subject with AKT1 and PIK3CA mutations.
  - Long-term disease stabilization and tumor shrinkage has been noted in subjects with lymphoma and other tumors.
- Patient accrual continues in subjects with AKT1 and PIK3CA mutations.

---

**OBJECTIVES**

- Safety and tolerability in subjects with cancers.
- Pharmacokinetic and pharmacodynamic activity; MTD and RP2D; preliminary evidence of activity.

**STUDY DESIGN AND METHODS**

- Extensive molecular evidence validates the pathway as a target in cancer.
- AKT signal pathway is aberrantly dysregulated in a wide range of tumor types.

---

**RESULTS**

As of 31 Aug 2015, 107 subjects have been enrolled and treated including 62 in the dose escalation cohorts and 25 in the expansion cohort.

### Table 5. Tumor Response in Expansion Cohort (%)

<table>
<thead>
<tr>
<th>PR</th>
<th>NE</th>
<th>PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>10%</td>
<td>25%</td>
</tr>
</tbody>
</table>

**CONCLUSIONS**

- ARO 092 has a manageable safety profile at the RP2Ds and schedules.
- The drug-related adverse events reported are hyperglycemia, skin rash, diarrhea, vomiting, mucositis and transaminase increase. Most of the adverse events are mild to moderate. The most common drug-related severe (Grade 3/4) adverse events include hyperglycemia and skin rash.
- Maximal plasma levels (Cmax) ranged from a mean of 1867 nm for the 200 mg QD, GW2 to a mean of 1403 nm for the 200 mg BID QW expansion cohorts.
- ARO 092 has demonstrated preliminary anti-cancer activities in the expansion cohort:
  - Partial responses have been observed in the expansion cohort in 4 subjects including 2 subjects with AKT1 E17K mutation (follicular lymphoma and breast), 1 subject with PIK3CA mutations, and 1 subject with AKT1 and PIK3CA mutations.
  - Long-term disease stabilization and tumor shrinkage has been noted in subjects with lymphoma and other tumors.
- Patient accrual continues in subjects with AKT1 and PIK3CA mutations.

---

**OBJECTIVES**

- Safety and tolerability in subjects with cancers.
- Pharmacokinetic and pharmacodynamic activity; MTD and RP2D; preliminary evidence of activity.

**STUDY DESIGN AND METHODS**

- Extensive molecular evidence validates the pathway as a target in cancer.
- AKT signal pathway is aberrantly dysregulated in a wide range of tumor types.

---

**RESULTS**

As of 31 Aug 2015, 107 subjects have been enrolled and treated including 62 in the dose escalation cohorts and 25 in the expansion cohort.

### Table 5. Tumor Response in Expansion Cohort (%)

<table>
<thead>
<tr>
<th>PR</th>
<th>NE</th>
<th>PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>10%</td>
<td>25%</td>
</tr>
</tbody>
</table>

**CONCLUSIONS**

- ARO 092 has a manageable safety profile at the RP2Ds and schedules.
- The drug-related adverse events reported are hyperglycemia, skin rash, diarrhea, vomiting, mucositis and transaminase increase. Most of the adverse events are mild to moderate. The most common drug-related severe (Grade 3/4) adverse events include hyperglycemia and skin rash.
- Maximal plasma levels (Cmax) ranged from a mean of 1867 nm for the 200 mg QD, GW2 to a mean of 1403 nm for the 200 mg BID QW expansion cohorts.
- ARO 092 has demonstrated preliminary anti-cancer activities in the expansion cohort:
  - Partial responses have been observed in the expansion cohort in 4 subjects including 2 subjects with AKT1 E17K mutation (follicular lymphoma and breast), 1 subject with PIK3CA mutations, and 1 subject with AKT1 and PIK3CA mutations.
  - Long-term disease stabilization and tumor shrinkage has been noted in subjects with lymphoma and other tumors.
- Patient accrual continues in subjects with AKT1 and PIK3CA mutations.